BRIP1 and Friedreich ataxia: In addition, we employed a re-expression strategy using either FANCJ KO or Fanconi anemia (FA) patient FANCJ deficient (FA-J) cells showing expected MMC sensitivity (Supplementary Fig. 2e–h) and PARPi resistance (Supplementary Fig. 2i).